Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06135350
Other study ID # 06-FT-2021, v. 3.0, 03.11.2022
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date November 2023
Est. completion date December 2024

Study information

Verified date November 2023
Source Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to evaluate the clinical and antibacterial efficacy, safety and pharmacokinetics of the drug Fluorothiazinone compared to placebo to prevent nosocomial gram-negative bacterial infections with participation of patients on mechanical ventilation. The main objectives of this study are: - Evaluation of the clinical and antibacterial efficacy of the drug Fluorothiazinone in combination with standard measures for the prevention of nosocomial infections compared to placebo in combination with standard measures for the prevention of nosocomial infections for the prevention of nosocomial infections caused by bacterial gram-negative flora in patients on mechanical ventilation. - Evaluation of the safety and tolerability of the drug Fluorothiazinone in patients on mechanical ventilation. - Evaluation of the pharmacokinetics (in whole blood) of the drug Fluorothiazinone with a single daily dose of 2400 mg/day. Researchers will compare results for the treatment and the placebo arms.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 234
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient's written consent to participate in the study in accordance with the current legislation or the decision of the board in case of absence of consciousness of the patient. 2. Patients are at least 18 years old, male and female. 3. Patients who are in the ICU (intensive care unit). 4. Patients with: 4.1. Laboratory confirmed SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus-2) on screening (a patient's coronavirus infection can be confirmed either before admission to the hospital (for outpatient treatment) or when admitted to the hospital) by RT-PCR (reverse transcription polymerase chain reaction) AND severe community-acquired pneumonia in ICU with evidence of viral lung injury and symptoms of respiratory failure: - SpO2 (peripheral oxygen saturation) = 93%; - Lung changes of 3rd- to 4th-degree according to CT (results of computed tomography), consistent with viral involvement; OR 4.2. Acute stroke; OR 4.3. Acute heart failure: Cardiogenic shock of any cause, pulmonary edema, or acute decompensated chronic heart failure. 5. Patients who have been on ALV (artificial lung ventilation) for no more than 12 hours. 6. Patients who are according to the investigator are at high risk to be transferred to ALV within 72 hours of the initiation of the therapy. 7. All women of childbearing age and men with partners of childbearing age should agree to use an effective contraceptive methods (e.g., implants, infections, combination oral contraceptives, intrauterine device, abstinence, vasectomy or vasectomy partner) during the entire study. Exclusion Criteria: 1. The patient was not switched to ALV within 72 hours (3 days) after receiving the investigational drug. 2. People who have a bloodstream infection, identified during the screening. 3. A patient may terminate his/her participation in the study at any time for any reason and without any explanation. 3. The investigator may also decide to terminate the patient's participation at any time if it is required due to the patient's condition. 4. The sponsor or the regulator may also request the trial to be terminated early, either due to how the trial was conducted, or due to application safety data, or other reasons. 5. The main reasons why the patient may withdraw from the study are: - Refusal of the patient to participate in the study; - Development of an AE (adverse event) / SAE (serious adverse event) that prevents further study participation; - The occurrence of concomitant somatic diseases / symptoms or exacerbation of chronic diseases not related to the investigational drug (at the discretion of the medical investigator).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose: 2400 mg/day (4 tablets twice a day) for the first 2 days and; 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons. Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days.
Other:
Placebo
Placebo arm patients will receive placebo: 4 tablets twice a day for the first 2 days and; 3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons. Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Outcome

Type Measure Description Time frame Safety issue
Other Comparative characteristics of colonization of the respiratory and urinary tracts Comparative characteristics of colonization of the respiratory and urinary tracts by individual pathogens in patients on the MV. Throughout the therapy period (14 days).
Other Comparative assessment of the condition on the SOFA scale Comparative assessment of the condition on the Sequential Organ Failure Assessment (SOFA) scale. Comparative assessment of the condition on the SOFA scale throughout the study. Score ranges from 0 (best) to 24 (worst) points. Throughout the therapy period (14 days).
Other Comparative assessment of the condition on the APACHE II scale Comparative assessment of the condition on the Acute Physiology and Chronic Health Evaluation II (APACHE II) scale throughout the study. Calculates an integer score from 0 to 71 based on multiple measurements. Higher scores correspond to more severe disease and a higher risk of death. Throughout the therapy period (14 days).
Primary MV-associated pneumonia caused by gram-negative bacteria (72-120 hours from the moment of tracheal intubation and the start of the MV) The proportion of patients in the study groups without clinically and microbiologically confirmed MV-associated pneumonia caused by gram-negative bacteria, which developed no earlier than 72 hours (3 days) and no later than 120 hours (5 days) from the moment of tracheal intubation and the start of the MV, in the absence of signs of pulmonary infection at the time of intubation. Throughout the therapy period (14 days).
Secondary Time from the beginning of the MV to the development of MV-associated pneumonia The time from the beginning of the MV to the development of MV-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, in the study groups during the entire period of therapy. Throughout the therapy period (14 days).
Secondary Time from the beginning of the MV to the development of a bloodstream infection The time from the beginning of the MV to the development of a bloodstream infection caused by gram-negative bacteria, confirmed microbiologically in the study groups during the entire period of therapy. Throughout the therapy period (14 days).
Secondary Time from the beginning of the MV to the development of urinary tract infection The time from the beginning of the MV to the development of urinary tract infection caused by gram-negative bacteria, confirmed microbiologically in the study groups during the entire period of therapy. Throughout the therapy period (14 days).
Secondary Proportion of patients who developed urinary tract infection The proportion of patients who developed urinary tract infection caused by gram-negative bacteria, confirmed microbiologically, in the study groups during the entire period of reception of the investigative drug (IMP). Throughout the therapy period (14 days).
Secondary Proportion of patients who did not develop MV-associated pneumonia The proportion of patients who did not develop MV-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, in the study groups during the entire period of reception of the investigative drug (IMP). Throughout the therapy period (14 days).
Secondary Proportion of patients who have gram-negative bacteria The proportion of patients who have gram-negative bacteria isolated from the respiratory tract, with no clinical picture of pneumonia. Throughout the therapy period (14 days).
Secondary Proportion of patients who developed a bloodstream infection (during the entire period of therapy) The proportion of patients who developed a bloodstream infection caused by gram-negative microflora, confirmed microbiologically in the study groups during the entire period of therapy. Throughout the therapy period (14 days).
Secondary Proportion of patients who developed a bloodstream infection (after the patient was transferred to the MV) The proportion of patients who developed a bloodstream infection caused by gram-negative microflora, confirmed microbiologically in the study groups after the patient was transferred to the MV. Throughout the therapy period (14 days).
Secondary Proportion of patients with septic complications The proportion of patients with septic complications in the study groups during the entire period of therapy. Throughout the therapy period (14 days).
Secondary The proportion of fatal outcomes The proportion of fatal outcomes in the study groups during the entire period of therapy. Throughout the therapy period (14 days).
See also
  Status Clinical Trial Phase
Completed NCT00723502 - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients Phase 2
Completed NCT00177814 - Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
Suspended NCT00563134 - A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult N/A
Active, not recruiting NCT05171257 - Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit
Completed NCT03160040 - A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting
Completed NCT02962934 - An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without CRRT
Enrolling by invitation NCT04055922 - Comparison of Solid Organ Transplant
Completed NCT00490477 - The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial Phase 3
Recruiting NCT04861922 - Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection Phase 3
Completed NCT01732250 - Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem Phase 4
Completed NCT00406198 - Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis Phase 4
Recruiting NCT06086626 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants Phase 2
Withdrawn NCT04785924 - Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections Phase 4
Completed NCT02285075 - Temocillin Pharmacokinetic in Hemodialysis Phase 4
Completed NCT03182504 - A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants Phase 1
Not yet recruiting NCT04917380 - The Clinical Character,Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Completed NCT03397914 - Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections Phase 4
Completed NCT02088840 - Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Stem Cell Transplant
Recruiting NCT01600768 - Evaluation of Extended Intravenous of Beta-lactams in the Treatment of Serious Gram-negative Infections in Critically Ill Patients N/A